AMO-18-005 Enhancing Safety and Benefit from Azathioprine Therapy for Our Inflammatory Bowel Disease Patients
Aze Wilson (pictured) + Richard B. Kim

New Technology, Therapies, eHealth & mHealth Aze Wilson azesuzanne.wilson@lhsc.on.ca 519-663-3832 Affiliation Academic Medical Organization of Southwestern Ontario Richard Kim richard.kim@lhsc.on.ca 519-663-3553 Affiliation Academic Medical Organization of Southwestern OntarioWe evaluated how HLA-DQA1-HLA-DRB1-screening can identify inflammatory bowel disease (IBD) patients at high-risk of azathioprine (AZA)-induced pancreatitis, a severe drug side effect....

View Project

AMO-17-012 Evaluation of a Novel Method and Drug Repositioning to Protect ex vivo Kidney for Transplantation
Patrick Luke

New Technology, Therapies, eHealth & mHealth Patrick Luke patrick.luke@lhsc.on.ca 519 663 3180 Affiliation Academic Medical Organization of Southwestern OntarioKidney transplantation is currently the best treatment option available for patients with kidney failure. Unfortunately, the need for kidneys is greater than the number of acceptable donors available. To increase access...

View Project

©2025 IFPOC - The Innovation Fund Provincial Oversight Committee - created by Techna

Log in with your credentials

Forgot your details?